1. Scrip
  2. >>Business
  3. >>Financing

The IPO Queue Fills Up, But A Recovery Is A Way Off

 
• By Elizabeth Cairns

Six biopharma companies have filed to list their shares on US exchanges so far this year, but the sums they are seeking are small.    

IPO
• Source: Shutterstock: stavklem

The past quarter has been a quiet period for biotech flotations, but perhaps the situation might improve in the coming months. Six companies have filed to go public on US exchanges since the start of this year, and one, Artiva Biotherapeutics, Inc., plans to raise $135m on 19 July.

Key Takeaways
  • Six companies have filed to list on Western exchanges so far this year.
  • In total they are seeking to raise just $271m.
  • Three could float this week.
    • ...

Artiva initially filed to go public last month, but has only just spelled out its plans in more detail. Its recent SEC filing specifies that it will sell 8.7 million...

More from Financing

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.